SEC Form 4 · accession 0001632388-15-000004
Nexvet Biopharma plc · NVET
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark Heffernan
Officer — Chief Executive Officer · Director
Period of report
Feb 10, 2015
Accepted (ET)
Feb 10, 2015 · 2:29 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001618561
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1,F2 | Feb 10, 2015 | C | 4,424 | — | A | 234,383 | I | By Mark Andrew and Patricia Louise Heffernan <M&T Heffernan A/C> |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Series A Investment Preference SharesF1,F2 | — | Feb 10, 2015 | C | 4,424 | D | — | — | Ordinary Shares | 4,424 | 0 | I |
Explanation of responses
- F1Reflects automatic conversion of Series A Investment Preference Shares into ordinary shares on a one-for-one basis upon the completion of the initial public offering of Issuer's ordinary shares.
- F2The reporting person and his spouse share voting and dispositive power with respect to the reported securities.